1. Home
  2. WDC vs BIIB Comparison

WDC vs BIIB Comparison

Compare WDC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Digital Corporation

WDC

Western Digital Corporation

N/A

Current Price

$313.51

Market Cap

137.0B

Sector

Technology

ML Signal

N/A

Logo Biogen Inc.

BIIB

Biogen Inc.

N/A

Current Price

$254.56

Market Cap

34.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WDC
BIIB
Founded
1970
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.0B
34.5B
IPO Year
2001
1996

Fundamental Metrics

Financial Performance
Metric
WDC
BIIB
Price
$313.51
$254.56
Analyst Decision
Buy
Buy
Analyst Count
26
36
Target Price
★ $613.38
$268.26
AVG Volume (30 Days)
★ 7.3M
1.2M
Earning Date
10-22-2026
10-28-2026
Dividend Yield
★ 0.24%
N/A
EPS Growth
★ 374.22
N/A
EPS
★ 4.63
2.66
Revenue
★ $12,919,000,000.00
$9,890,600,000.00
Revenue This Year
$64.99
$6.92
Revenue Next Year
$40.49
$1.91
P/E Ratio
★ $62.17
$95.38
Revenue Growth
★ 35.70
2.22
52 Week Low
$132.43
$160.36
52 Week High
$799.87
$261.00

Technical Indicators

Market Signals
Indicator
WDC
BIIB
Relative Strength Index (RSI) 41.33 60.95
Support Level $246.63 $186.24
Resistance Level $483.67 $258.78
Average True Range (ATR) 23.96 8.45
MACD -3.63 -0.31
Stochastic Oscillator 37.98 70.29

Price Performance

Historical Comparison
WDC
BIIB

About WDC Western Digital Corporation

Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is essentially a duopoly, with Western Digital and Seagate as the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. Data centers are the primary consumers of HDDs.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: